1. Home
  2. KRRO vs VRXA Comparison

KRRO vs VRXA Comparison

Compare KRRO & VRXA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Korro Bio Inc.

KRRO

Korro Bio Inc.

SELL

Current Price

$12.67

Market Cap

196.4M

Sector

Health Care

ML Signal

SELL

Logo Veraxa Biotech AG Ordinary Shares

VRXA

Veraxa Biotech AG Ordinary Shares

HOLD

Current Price

$1.05

Market Cap

161.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KRRO
VRXA
Founded
2014
2021
Country
United States
Germany
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
196.4M
161.2M
IPO Year
2019
2025

Fundamental Metrics

Financial Performance
Metric
KRRO
VRXA
Price
$12.67
$1.05
Analyst Decision
Strong Buy
Analyst Count
11
0
Target Price
★ $21.50
N/A
AVG Volume (30 Days)
★ 212.2K
152.5K
Earning Date
11-05-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $6,392,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 181.46
N/A
52 Week Low
$5.20
$0.90
52 Week High
$17.35
$4.50

Technical Indicators

Market Signals
Indicator
KRRO
VRXA
Relative Strength Index (RSI) 48.28 46.93
Support Level $11.81 $0.96
Resistance Level $14.47 $1.25
Average True Range (ATR) 1.45 0.12
MACD -0.22 0.03
Stochastic Oscillator 24.60 37.23

Price Performance

Historical Comparison
KRRO
VRXA

About KRRO Korro Bio Inc.

Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.

About VRXA Veraxa Biotech AG Ordinary Shares

Veraxa Biotech Holding AG focus on antibody therapies in medicine. The Company is an oncology-focused biotechnology Company with a clinical program in acute myeloid leukemia and two proprietary platform technologies that enable the development of new generations of antibody drug conjugates (ADC's) and T cell engagers. The Company operates in one reportable segment, focused on the research and development of products for the aging population.

Share on Social Networks: